Stockscreener 앱 받기
0.00
100.00%
-0.695
전일 마감가:
$0.695
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
$398.00K
순이익/손실:
$-28.92M
주가수익비율:
0.00
EPS:
-12.9458
순현금흐름:
$-28.98M
1주 성능:
-100.00%
1개월 성능:
-72.34%
6개월 성능:
-93.96%
1년 성능:
-95.42%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$0.695
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Compare LYRA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.00 | 0 | 398.00K | -28.92M | -28.98M | -12.95 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-05-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-05-06 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | 재개 | BTIG Research | Buy |
| 2023-08-31 | 개시 | H.C. Wainwright | Buy |
| 2022-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 개시 | BTIG Research | Buy |
| 2020-05-26 | 개시 | BofA/Merrill | Buy |
| 2020-05-26 | 개시 | Jefferies | Buy |
| 2020-05-26 | 개시 | William Blair | Outperform |
모두보기
Lyra Therapeutics Inc 주식(LYRA)의 최신 뉴스
LYRA THERAPEUTICS INC by Lyra Therapeutics, Inc. Market Sentiment - Benzinga
LYRA stock rises on Lyra Therapeutics trial and cash data - AD HOC NEWS
Layoff Tracker: EMD Serono may trim R&D workforce by up to 70 - BioSpace
Enterprise value to EBIT forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Lyra Therapeutics stock trades steadily as sinusitis implant program advances - Ad-hoc-news.de
Price to earnings forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Enterprise value to EBITDA forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Enterprise value to revenue forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Price to sales forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
LYRA stock tracks Lyra Therapeutics after recent filing context. - Ad Hoc News
Lyra Therapeutics, Inc. Actuals & Estimates (OTC:LYRA) - TradingView
Lyra Therapeutics Inc (LYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LYRA Forecast — Price Target — Prediction for 2027 - TradingView
Lyra Therapeutics Inc (LYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lyra Therapeutics Inc (LYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lyra Therapeutics Inc (LYRA) Institutional Confidence - TradingKey
Lyra Therapeutics Inc (LYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lyra Therapeutics Inc (LYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyra Therapeutics Inc (LYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyra Therapeutics Inc (LYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lyra Therapeutics Inc (LYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Fulcrum shrinks headcount 85% - Fierce Biotech
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates - MSN
Lyra Therapeutics (LYRA) director surrenders 640 shares to issuer - Stock Titan
Lyra Therapeutics Inc (OTCM:LYRA) SEC filings - GuruFocus
Lyra Therapeutics Inc (OTCM:LYRA) Stock Price & 30 Year Financial Data - GuruFocus
Lyra Therapeutics Inc (LYRA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Lyra Therapeutics Inc (OTCM:LYRA) Stock Earnings Transcripts - GuruFocus
Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - MSN
[15-12G] Lyra Therapeutics, Inc. SEC Filing - Stock Titan
6 biotechs that called it quits in Q1 - BioSpace
Lyra Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - MSN
Total common shares outstanding of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
Lyra Therapeutics (NASDAQ: LYRA) files Form 25 to delist from Nasdaq Capital Market - Stock Titan
Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC - Sahm
Lyra Therapeutics to delist from Nasdaq, suspend SEC reporting By Investing.com - Investing.com India
Lyra Therapeutics (LYRA) Plans Voluntary Delisting from Nasdaq - GuruFocus
Lyra Therapeutics ends Waltham sublease, agrees to $2.1 million termination payment - Investing.com
Lyra Therapeutics Ends Major Office Sublease Agreement - TipRanks
Lyra Therapeutics (NASDAQ: LYRA) pays $2.1M to exit Waltham lease - Stock Titan
Lyra Therapeutics to delist from Nasdaq, suspend SEC reporting - Investing.com
Lyra Therapeutics, Inc. Announces Intention to Voluntarily - GlobeNewswire
After layoffs, biotech exits 2 Boston-area leases - NBC Boston
After layoffs, Lyra Therapeutics exits Watertown and Waltham leases - The Business Journals
Analyst Upgrade: Is BioRestorative Therapies Inc still a buy after recent gainsInsider Selling & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Lyra Therapeutics Streamlines Operations with Major Lease Terminations - The Globe and Mail
Lyra Therapeutics to end leases early for Watertown and Waltham facilities By Investing.com - Investing.com South Africa
Lyra Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Stock Info, and Key Disclosures (March 31, 2026) - Minichart
Lyra Therapeutics to end leases early for Watertown and Waltham facilities - Investing.com
Lyra Therapeutics (NASDAQ: LYRA) exits two office leases early - Stock Titan
Lyra Therapeutics Inc (LYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.46%
0.84%
자본화:
|
볼륨(24시간):